ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1271

Uptake of Rheumatology-Specific Quality Measures Submitted to National Pay-for-Performance Programs: An Analysis of Participants in the RISE Registry

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1478

Urine ALCAM Is a Strong Predictor of Lupus Nephritis

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1135

Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy

Genetics, Genomics and Proteomics Poster

1:00PM-3:00PM: Abstract Number: 1359

Usability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1210

Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1533

Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1519

Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1448

Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1159

Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1242

Validation of a Novel Ultrasound Scoring System for the Evaluation of Pediatric Knee Arthritis

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1562

Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1199

Validation of New Medication User Definitions in Single-Specialty EHR Data

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1198

Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1362

Validation of the 2016 ACR/EULAR Myositis Response Criteria in Juvenile Dermatomyositis (JDM) Clinical Trials and Consensus Profiles

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1517

Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].